I find it a little difficult to see how things will ultimately play out with this Covid trial.

We’ve started a trial that is expected to last approximately 2-3 months, however at this stage the expectation is that numbers of people hospitalized with Omicron will naturally start to decline over this period.  We could end up with another variant (God forbid) at any time of course, but for now it seems we are having to move quickly before the number of eligible Omicron candidates begins to decline.  But ok, we deal with we’re we are at and its likely that pockets of severe Covid will be with us for some time yet to meet the 100 patient quota for this trial.

In the event we are successful in demonstrating that ABL has the desired positive effect on Covid, what does that look like in terms of a possible valuation?  Do we go from a 0.50 cent SP to $1, $2?, $5? or beyond?  And what about the warrants that expire in June 2023?  We would have to get an extremely major bounce in the SP (probably above $4,60) to make those pay off in any meaningful way.  It seems to me that if we are successful in Canada with this trial then we shouldn’t have to wait 6 months for the US trial before we start seeing the impact on the SP.

I think the one thing we can predict is that a successful Covid trial will significantly raise the profile of RVX and, by extension, the BoM2 trial.  Besides help in nailing down the financing for that it should also beef up the SP to something that is much more interesting than $0.50/share, but again by how much is anyone’s guess.  I certainly have no idea.